Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG)

CAPS Rating: 1 out of 5

The Company is seeking to develop and commercialize new diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs.

Recs

1
Player Avatar zzlangerhans (99.74) Submitted: 2/28/2011 3:53:55 PM : Underperform Start Price: $33.00 ROSG Score: +8.91

I'm really not sure why Rosetta Genomics is a public company. The share price has followed a steady downward trajectory since the IPO, and all the company has accomplished is the development of some microRNA cancer screening tests that no one is buying. It doesn't appear they have any other technology or any prospects for commercial success. With 5M in cash, it appears they may be entering a death spiral of dilutions and staff cuts. The only question here is if their platform is worth enough for someone like Alnylam or Isis to buy them out at a price substantially higher than their 9M cap. From that perspective, this is a very risky red thumb.

Report this Post 2 Replies
Member Avatar mjonesy1985 (94.55) Submitted: 3/2/2011 7:36:47 PM
Recs: 0

he who trades only solid companies and solid companies only will not be in the market for long.....

Member Avatar zzlangerhans (99.74) Submitted: 3/2/2011 11:16:38 PM
Recs: 1

Fortunately it's free to write pitch replies. You've spent nothing to spew complete and utter nonsense.

Featured Broker Partners


Advertisement